Loading…

Early gastric cancer in Europe

Despite mass population screening and an incidence of EGC in Japan that is at least double that of the West, there seem to be no genuine differences in the clinicopathological features of the disease between the two regions. The macroscopic appearance, size, depth of invasion, frequency of lymph nod...

Full description

Saved in:
Bibliographic Details
Published in:Gut 1997-08, Vol.41 (2), p.142-150
Main Authors: EVERETT, S M, AXON, A T R
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b600t-a394c24905ce7b228b4a04f631796c5adf165f8d20b3c1463e8422264ee3df0f3
cites
container_end_page 150
container_issue 2
container_start_page 142
container_title Gut
container_volume 41
creator EVERETT, S M
AXON, A T R
description Despite mass population screening and an incidence of EGC in Japan that is at least double that of the West, there seem to be no genuine differences in the clinicopathological features of the disease between the two regions. The macroscopic appearance, size, depth of invasion, frequency of lymph node invasion, and histology of EGC are all remarkably similar in Japan, Europe and America, as are sex and age distributions. Patients with EGC are a number of years younger than those with advanced cancer. This is not surprising: Tsukuma et alfollowed 56 cases of EGC that were not surgically treated and estimated that the median “duration of EGC” before becoming advanced was 37 months.87 This suggests that EGC undergoes a period of slow growth before becoming advanced. Further differences between early and advanced cancers include a higher frequency of synchronous cancers and a longer symptom duration in EGC. Unfavourable prognostic factors in EGC include lymph node invasion, and invasion through the muscularis mucosae, though it is not clear whether these are independent. Repeated attempts have been made to identify other prognostic factors, but no clear pattern has emerged, with the possible exceptions of patient age, tumour size, and the presence of ulceration. The postsurgical outcome of EGC in the West is marginally less favourable than in Japan. In view of the similar clinical and pathological features in the two regions it seems likely, therefore, that this is because of the more aggressive surgical techniques traditionally used in Japan. Conversely, however, EMR has recently emerged as an important technique in Japan. Despite the advantages of low operative mortality and normal function of the postoperative stomach, there are also a number of potential disadvantages. It would seem sensible, therefore, to await the results of long term follow up studies before widespread adoption of EMR in Europe. Nevertheless, this technique should be considered for frail patients unfit for more radical surgery.
doi_str_mv 10.1136/gut.41.2.142
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1891459</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3984270631</sourcerecordid><originalsourceid>FETCH-LOGICAL-b600t-a394c24905ce7b228b4a04f631796c5adf165f8d20b3c1463e8422264ee3df0f3</originalsourceid><addsrcrecordid>eNp9kc9rE0EYhodiadPam9dKwGIvbvy--T0XQUJshaI9aClehtnJbNy42Y0zu2L_eyckhNZDT9_hfXh4P15CXiFMEJl8vxj6CccJnSCnB2SEXOqCUa1fkBEAqkIobo7JSUpLANDa4BE5MgyQGxiR1zMXm4fxwqU-1n7sXetDHNfteDbEbh1eksPKNSmc7e4p-f5p9m16Xdx8vfo8_XhTlBKgLxwz3NMsFD6oklJdcge8kgyVkV64eYVSVHpOoWQ-F2RBc0qp5CGweQUVOyUftt71UK7C3Ie2j66x61ivXHywnavt06Stf9pF98di_ocLkwVvd4LY_R5C6u2qTj40jWtDNySrDDUMgWfwzX_gshtim5-zqDSgBCrU85RiFJTgIlPvtpSPXUoxVPvCCHazjc3bWI6W2rxNxs8fP7mHd2Pk_GKXu-RdU8U8Rp32GM3tDG40xRarUx_-7mMXf1mpmBL2y93UGkHF7e2Pe7tpebnly9Xy-YL_AJqJr2s</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1773207545</pqid></control><display><type>article</type><title>Early gastric cancer in Europe</title><source>PubMed Central</source><creator>EVERETT, S M ; AXON, A T R</creator><creatorcontrib>EVERETT, S M ; AXON, A T R</creatorcontrib><description>Despite mass population screening and an incidence of EGC in Japan that is at least double that of the West, there seem to be no genuine differences in the clinicopathological features of the disease between the two regions. The macroscopic appearance, size, depth of invasion, frequency of lymph node invasion, and histology of EGC are all remarkably similar in Japan, Europe and America, as are sex and age distributions. Patients with EGC are a number of years younger than those with advanced cancer. This is not surprising: Tsukuma et alfollowed 56 cases of EGC that were not surgically treated and estimated that the median “duration of EGC” before becoming advanced was 37 months.87 This suggests that EGC undergoes a period of slow growth before becoming advanced. Further differences between early and advanced cancers include a higher frequency of synchronous cancers and a longer symptom duration in EGC. Unfavourable prognostic factors in EGC include lymph node invasion, and invasion through the muscularis mucosae, though it is not clear whether these are independent. Repeated attempts have been made to identify other prognostic factors, but no clear pattern has emerged, with the possible exceptions of patient age, tumour size, and the presence of ulceration. The postsurgical outcome of EGC in the West is marginally less favourable than in Japan. In view of the similar clinical and pathological features in the two regions it seems likely, therefore, that this is because of the more aggressive surgical techniques traditionally used in Japan. Conversely, however, EMR has recently emerged as an important technique in Japan. Despite the advantages of low operative mortality and normal function of the postoperative stomach, there are also a number of potential disadvantages. It would seem sensible, therefore, to await the results of long term follow up studies before widespread adoption of EMR in Europe. Nevertheless, this technique should be considered for frail patients unfit for more radical surgery.</description><identifier>ISSN: 0017-5749</identifier><identifier>EISSN: 1468-3288</identifier><identifier>EISSN: 1458-3288</identifier><identifier>DOI: 10.1136/gut.41.2.142</identifier><identifier>PMID: 9301490</identifier><identifier>CODEN: GUTTAK</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Society of Gastroenterology</publisher><subject>Biological and medical sciences ; Europe - epidemiology ; Gastric Mucosa - pathology ; Gastroenterology. Liver. Pancreas. Abdomen ; Humans ; Incidence ; Japan - epidemiology ; Lymphatic Metastasis ; Mass Screening ; Medical sciences ; Review ; Stomach Neoplasms - epidemiology ; Stomach Neoplasms - mortality ; Stomach Neoplasms - pathology ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Survival Rate ; Tumors</subject><ispartof>Gut, 1997-08, Vol.41 (2), p.142-150</ispartof><rights>British Society of Gastroenterology</rights><rights>1997 INIST-CNRS</rights><rights>Copyright: 1997 British Society of Gastroenterology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b600t-a394c24905ce7b228b4a04f631796c5adf165f8d20b3c1463e8422264ee3df0f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1891459/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1891459/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,313,314,727,780,784,792,885,27922,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2801912$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9301490$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>EVERETT, S M</creatorcontrib><creatorcontrib>AXON, A T R</creatorcontrib><title>Early gastric cancer in Europe</title><title>Gut</title><addtitle>Gut</addtitle><description>Despite mass population screening and an incidence of EGC in Japan that is at least double that of the West, there seem to be no genuine differences in the clinicopathological features of the disease between the two regions. The macroscopic appearance, size, depth of invasion, frequency of lymph node invasion, and histology of EGC are all remarkably similar in Japan, Europe and America, as are sex and age distributions. Patients with EGC are a number of years younger than those with advanced cancer. This is not surprising: Tsukuma et alfollowed 56 cases of EGC that were not surgically treated and estimated that the median “duration of EGC” before becoming advanced was 37 months.87 This suggests that EGC undergoes a period of slow growth before becoming advanced. Further differences between early and advanced cancers include a higher frequency of synchronous cancers and a longer symptom duration in EGC. Unfavourable prognostic factors in EGC include lymph node invasion, and invasion through the muscularis mucosae, though it is not clear whether these are independent. Repeated attempts have been made to identify other prognostic factors, but no clear pattern has emerged, with the possible exceptions of patient age, tumour size, and the presence of ulceration. The postsurgical outcome of EGC in the West is marginally less favourable than in Japan. In view of the similar clinical and pathological features in the two regions it seems likely, therefore, that this is because of the more aggressive surgical techniques traditionally used in Japan. Conversely, however, EMR has recently emerged as an important technique in Japan. Despite the advantages of low operative mortality and normal function of the postoperative stomach, there are also a number of potential disadvantages. It would seem sensible, therefore, to await the results of long term follow up studies before widespread adoption of EMR in Europe. Nevertheless, this technique should be considered for frail patients unfit for more radical surgery.</description><subject>Biological and medical sciences</subject><subject>Europe - epidemiology</subject><subject>Gastric Mucosa - pathology</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Humans</subject><subject>Incidence</subject><subject>Japan - epidemiology</subject><subject>Lymphatic Metastasis</subject><subject>Mass Screening</subject><subject>Medical sciences</subject><subject>Review</subject><subject>Stomach Neoplasms - epidemiology</subject><subject>Stomach Neoplasms - mortality</subject><subject>Stomach Neoplasms - pathology</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Survival Rate</subject><subject>Tumors</subject><issn>0017-5749</issn><issn>1468-3288</issn><issn>1458-3288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNp9kc9rE0EYhodiadPam9dKwGIvbvy--T0XQUJshaI9aClehtnJbNy42Y0zu2L_eyckhNZDT9_hfXh4P15CXiFMEJl8vxj6CccJnSCnB2SEXOqCUa1fkBEAqkIobo7JSUpLANDa4BE5MgyQGxiR1zMXm4fxwqU-1n7sXetDHNfteDbEbh1eksPKNSmc7e4p-f5p9m16Xdx8vfo8_XhTlBKgLxwz3NMsFD6oklJdcge8kgyVkV64eYVSVHpOoWQ-F2RBc0qp5CGweQUVOyUftt71UK7C3Ie2j66x61ivXHywnavt06Stf9pF98di_ocLkwVvd4LY_R5C6u2qTj40jWtDNySrDDUMgWfwzX_gshtim5-zqDSgBCrU85RiFJTgIlPvtpSPXUoxVPvCCHazjc3bWI6W2rxNxs8fP7mHd2Pk_GKXu-RdU8U8Rp32GM3tDG40xRarUx_-7mMXf1mpmBL2y93UGkHF7e2Pe7tpebnly9Xy-YL_AJqJr2s</recordid><startdate>19970801</startdate><enddate>19970801</enddate><creator>EVERETT, S M</creator><creator>AXON, A T R</creator><general>BMJ Publishing Group Ltd and British Society of Gastroenterology</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19970801</creationdate><title>Early gastric cancer in Europe</title><author>EVERETT, S M ; AXON, A T R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b600t-a394c24905ce7b228b4a04f631796c5adf165f8d20b3c1463e8422264ee3df0f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Biological and medical sciences</topic><topic>Europe - epidemiology</topic><topic>Gastric Mucosa - pathology</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Humans</topic><topic>Incidence</topic><topic>Japan - epidemiology</topic><topic>Lymphatic Metastasis</topic><topic>Mass Screening</topic><topic>Medical sciences</topic><topic>Review</topic><topic>Stomach Neoplasms - epidemiology</topic><topic>Stomach Neoplasms - mortality</topic><topic>Stomach Neoplasms - pathology</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Survival Rate</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>EVERETT, S M</creatorcontrib><creatorcontrib>AXON, A T R</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Science Journals</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Gut</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>EVERETT, S M</au><au>AXON, A T R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early gastric cancer in Europe</atitle><jtitle>Gut</jtitle><addtitle>Gut</addtitle><date>1997-08-01</date><risdate>1997</risdate><volume>41</volume><issue>2</issue><spage>142</spage><epage>150</epage><pages>142-150</pages><issn>0017-5749</issn><eissn>1468-3288</eissn><eissn>1458-3288</eissn><coden>GUTTAK</coden><abstract>Despite mass population screening and an incidence of EGC in Japan that is at least double that of the West, there seem to be no genuine differences in the clinicopathological features of the disease between the two regions. The macroscopic appearance, size, depth of invasion, frequency of lymph node invasion, and histology of EGC are all remarkably similar in Japan, Europe and America, as are sex and age distributions. Patients with EGC are a number of years younger than those with advanced cancer. This is not surprising: Tsukuma et alfollowed 56 cases of EGC that were not surgically treated and estimated that the median “duration of EGC” before becoming advanced was 37 months.87 This suggests that EGC undergoes a period of slow growth before becoming advanced. Further differences between early and advanced cancers include a higher frequency of synchronous cancers and a longer symptom duration in EGC. Unfavourable prognostic factors in EGC include lymph node invasion, and invasion through the muscularis mucosae, though it is not clear whether these are independent. Repeated attempts have been made to identify other prognostic factors, but no clear pattern has emerged, with the possible exceptions of patient age, tumour size, and the presence of ulceration. The postsurgical outcome of EGC in the West is marginally less favourable than in Japan. In view of the similar clinical and pathological features in the two regions it seems likely, therefore, that this is because of the more aggressive surgical techniques traditionally used in Japan. Conversely, however, EMR has recently emerged as an important technique in Japan. Despite the advantages of low operative mortality and normal function of the postoperative stomach, there are also a number of potential disadvantages. It would seem sensible, therefore, to await the results of long term follow up studies before widespread adoption of EMR in Europe. Nevertheless, this technique should be considered for frail patients unfit for more radical surgery.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Society of Gastroenterology</pub><pmid>9301490</pmid><doi>10.1136/gut.41.2.142</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0017-5749
ispartof Gut, 1997-08, Vol.41 (2), p.142-150
issn 0017-5749
1468-3288
1458-3288
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1891459
source PubMed Central
subjects Biological and medical sciences
Europe - epidemiology
Gastric Mucosa - pathology
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Incidence
Japan - epidemiology
Lymphatic Metastasis
Mass Screening
Medical sciences
Review
Stomach Neoplasms - epidemiology
Stomach Neoplasms - mortality
Stomach Neoplasms - pathology
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Survival Rate
Tumors
title Early gastric cancer in Europe
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T19%3A52%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20gastric%20cancer%20in%20Europe&rft.jtitle=Gut&rft.au=EVERETT,%20S%20M&rft.date=1997-08-01&rft.volume=41&rft.issue=2&rft.spage=142&rft.epage=150&rft.pages=142-150&rft.issn=0017-5749&rft.eissn=1468-3288&rft.coden=GUTTAK&rft_id=info:doi/10.1136/gut.41.2.142&rft_dat=%3Cproquest_pubme%3E3984270631%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b600t-a394c24905ce7b228b4a04f631796c5adf165f8d20b3c1463e8422264ee3df0f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1773207545&rft_id=info:pmid/9301490&rfr_iscdi=true